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Validating estimates of prevalence of
non-communicable diseases based on household
surveys: the symptomatic diagnosis study
Spencer L James1,2, Minerva Romero3, Dolores Ramírez-Villalobos4, Sara Gómez5, Kelsey Pierce1,
Abraham Flaxman1, Peter Serina1, Andrea Stewart1, Christopher JL Murray1, Emmanuela Gakidou1,
Rafael Lozano1,4 and Bernardo Hernandez1*
Abstract
Background: Easy-to-collect epidemiological information is critical for the more accurate estimation of the
prevalence and burden of different non-communicable diseases around the world. Current measurement is
restricted by limitations in existing measurement systems in the developing world and the lack of biometry tests for
non-communicable diseases. Diagnosis based on self-reported signs and symptoms (“Symptomatic Diagnosis,” or
SD) analyzed with computer-based algorithms may be a promising method for collecting timely and reliable
information on non-communicable disease prevalence. The objective of this study was to develop and assess
the performance of a symptom-based questionnaire to estimate prevalence of non-communicable diseases in
low-resource areas.
Methods: As part of the Population Health Metrics Research Consortium study, we collected 1,379 questionnaires
in Mexico from individuals who suffered from a non-communicable disease that had been diagnosed with gold
standard diagnostic criteria or individuals who did not suffer from any of the 10 target conditions. To make the
diagnosis of non-communicable diseases, we selected the Tariff method, a technique developed for verbal autopsy
cause of death calculation. We assessed the performance of this instrument and analytical techniques at the
individual and population levels.
Results: The questionnaire revealed that the information on health care experience retrieved achieved 66.1%
(95% uncertainty interval [UI], 65.6–66.5%) chance corrected concordance with true diagnosis of non-communicable
diseases using health care experience and 0.826 (95% UI, 0.818–0.834) accuracy in its ability to calculate fractions of
different causes. SD is also capable of outperforming the current estimation techniques for conditions estimated by
questionnaire-based methods.
Conclusions: SD is a viable method for producing estimates of the prevalence of non-communicable diseases in
areas with low health information infrastructure. This technology can provide higher-resolution prevalence data,
more flexible data collection, and potentially individual diagnoses for certain conditions.
Keywords: Automated methods, Mexico, Non-communicable diseases, Non-communicable diseases prevalence,
Questionnaire
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Background
Non-communicable diseases (NCDs) form a substantial
part of the global burden of disease in both developing
and developed countries, with certain NCDs posing an
equal or greater threat in low-income compared to high-
income countries [1]. Mexico, and much of Latin America
in general, have seen a relative increase in their NCD bur-
den in the past 20 years, with conditions such as heart
disease, arthritis, and vision loss steadily increasing in
terms of disability-adjusted life years [1].
Despite the substantial burden of NCDs around the
world, it continues to be difficult to collect accurate infor-
mation on their prevalence, particularly in areas that lack
consistent or accessible health care. In part, this is due to
inherent limitations in diagnosing these conditions.
While information on some infectious diseases, such as
HIV, malaria, and tuberculosis, can be collected through
biological assays or cultures, such an equivalent does not
exist for certain NCDs. The diagnostic criteria for a con-
dition such as chronic obstructive pulmonary disease
(COPD), for example, require medical resources such
as spirometry or medical knowledge to interpret FEV1/
FVC ratios and differentiate COPD from asthma based
on subtle differences in clinical signs and symptoms.
Moreover, medical diagnostic tests for NCDs, when ex-
istent, are frequently more expensive than for infectious
diseases, so surveys tend not to include them; for example,
a rapid diagnostic test for malaria costs less than $1 USD
in most countries [2], whereas the costs to obtain and
measure liver function tests or conduct a 12-lead electro-
cardiogram are much higher.
Cheaper tests, such as blood pressure and height and
weight, are included in many more surveys than the
more expensive ones like lipids or blood sugar. Despite
these challenges of measuring NCDs, epidemiological
studies endeavor to measure the prevalence of condi-
tions, such as asthma [3], depression [4,5], rheumatoid
arthritis [6], and COPD [7], in many areas of the devel-
oping world. However, there are still significant data
gaps and the methods used in these studies have not al-
ways been validated against a gold standard clinical and
pathological diagnosis. Thus, given that NCDs contri-
bute significantly to the global burden of disease, and
given that the diagnosis of NCDs requires clinical ex-
pertise and medical resources, the analytic question in
this study is whether self-reported signs and symptoms
in a questionnaire survey can be accurately assessed by
data-driven computational models in order to better mea-
sure the burden of these diseases.
Using computers to aid in medical diagnosis has been
discussed and explored for decades, ranging from early
articles that examined medical “indices” [8], the possibil-
ity of diagnostic “machines” [9,10], and the statistics that
would feed into diagnostic models [11]. More recently,
computational techniques have been implemented for
clinical tasks including data-based tasks such as identi-
fying arrhythmias in electrocardiogram tracings and inter-
pretation of computed tomography scans, symptom-based
tasks such as predicting maternal morbidity [12], diagnos-
ing asthma [13], and assessing common complaints in an
emergency department [14], and for patient-focused tasks,
e.g., symptom-based questionnaires such as WebMD and
SymCat.
For epidemiological purposes, certain studies meas-
ure disease burden based on questionnaire responses,
for example, the World Health Survey [15]. Diagnostic
classification-given questionnaire-based signs and symp-
toms have been tested in verbal autopsy (VA) research. In
VA studies, interviewers ask family members questions
about the signs and symptoms leading up to a death that
occurred in the household, and physicians or computer
models can be used to classify the estimated cause of
death. The advent of advanced computer techniques for
solving this problem are described elsewhere [16-22], in-
cluding a comparison of the performance of different
methods and physician-certified VA [23]. This research
has provided compelling evidence that computer algo-
rithms can match or outperform physician-certified VA.
Although this finding refers to deaths occurred in hospital
settings, and further research to test external validity may
be required, it bodes well for the idea that computers can
also be used for diagnosing NCDs in the living.
This study has two main objectives; first, to develop a
questionnaire based on self-reported signs and symptoms
and apply an automated technique to estimate the pre-
valence of NCDs in low-resource settings and, second,
to assess the performance of both the questionnaire
and the analytical technique at the individual and popu-
lation level. We refer to this method as “Symptomatic
Diagnosis” (SD).
Methods
Overview of study design
The SD study consisted of two components: data collec-
tion and model validation. The data collection portion
consisted of identifying cases of different NCDs in a hos-
pital and then conducting a questionnaire with the pa-
tient at a later date. The data were collected in Mexico
as part of the Population Health Metrics Research Con-
sortium (PHMRC) Study [22]. The PHMRC Study is an
offshoot of the Gates Grand Challenge 13 PHMRC Pro-
ject, an international collaborative focused on developing
better ways to measure health. The model validation com-
ponent used this validation data to test different approa-
ches to the analytical question of interest.
The SD study developed a questionnaire that focused on
10 NCDs, namely angina pectoris (ICD-10 I20.9), rheu-
matoid arthritis (ICD-10 M05-M06), cataracts (ICD-10
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H25-H26, H28, Q12.0), asthma (ICD-10 J45), COPD
(ICD-10 J40-J44, J47), symptomatic cirrhosis (ICD-
10 K70.3, K71.7, K74), vision loss (ICD-10 H54), hear-
ing loss (ICD-10 H90-H91), depression (ICD-10 F32,
F33), and osteoarthritis (ICD-10 M15-M19, M47). These
causes were chosen since they contribute considerably
to the burden of disease in Mexico, and because cur-
rent methods for collecting prevalence data on these
conditions are expensive and time-consuming. This
questionnaire also collected socio-demographic infor-
mation. The questionnaire was adapted from the World
Health Survey [15] and the PHMRC Household Survey
[24]. Information on the signs and symptoms of the re-
spondent is collected, but the questionnaire also asks
questions that relate to the respondent’s experience, if
any, with health care providers (health care experience;
HCE). These questions ask about whether the respond-
ent has ever been diagnosed with different conditions,
and whether certain medical procedures or protocols
have occurred. The list of items relevant to ascertain
the presence of a disease in the questionnaire and HCE
indicators is provided in Additional file 1.
Procedure
Data collection involved three stages: identifying cases
for the 10 conditions of interest, identifying controls
who did not suffer from any of the NCDs, and then
implementing the SD questionnaire at the household of
each case and each control.
Cases
A team of trained coders located approximately 1,200
cases (120 of each of the morbid conditions under study)
in 11 public hospitals in the Mexico City area and 120
cases of depression from a psychiatric hospital.
For each condition, a case was defined to be a patient
that a physician had diagnosed with the condition and
who met a specific set of gold standard diagnosis criteria
that was decided on by the PHMRC team. A gold stand-
ard diagnosis refers to diagnosis of a specific disease
with the highest level of accuracy possible. This involves
checking that the diagnosis is based on positive results
from a laboratory test or appropriate cabinet and/or
checking that the recording and documentation of the
appropriate symptoms of the disease were observed dur-
ing the development of clinical records. To be accept-
able, the symptoms of the disease must be observed or
documented in a medical record by a physician. The
gold standard criteria for each condition are provided in
Additional file 2.
We only included cases living in Mexico City who had
an address that was identifiable through the hospital re-
cords. Once the cases were identified, an interviewer
visited each household to administer a SD question-
naire to the cases.
Controls
We located a population of controls from the records of
the Automated Detection and Diagnosis Clinic (CLIDDA)
in Mexico City. CLIDDA performs a battery of diagnostic
tests on people who are affiliated with the Instituto de Se-
guridad y Servicios Sociales para los Trabajadores del
Estado. We defined a control to be someone who attended
the CLIDDA in the last 6 months prior to the data collec-
tion, was diagnosed as not having any history of the mor-
bid conditions being studied, was within a similar sex
distribution and age range as the cases, was living in the
urban area of Mexico City, and whose address was loca-
table from the CLIDDA records. Individuals with an ob-
vious other disease were not included. We identified a
sample of 240 controls. Once the controls were identified
by trained coders from the CLIDDA records, appoint-
ments were made, and an interviewer visited each house-
hold to administer an SD questionnaire.
Signed informed consent was obtained prior to each
interview. The project was approved by the institutional
review board of the University of Washington and by
the research, ethics, and biosafety committees of the
National Institute of Public Health, Mexico, and partici-
pant institutions.
Processing
The SD dataset was processed into a format usable by
statistical models using the same protocol as described
in the PHMRC VA study [22]. Specifically, the duration or
continuous survey items are converted to a dichotomous
“long duration” item using a median absolute deviation es-
timator, where the item is considered to be endorsed if it
is greater than the long duration cutoff. Cutoffs used in
this study are presented in Additional file 3. Categorical
items are expanded into being separate dichotomous
items for each level or category of the item. For the pur-
pose of clarity, the term “feature” will be used to refer to
the dichotomized (endorsed versus not endorsed) items or
information used by the model/estimation process, while
the term “cause” will be used to refer to “condition” or
“illness” or to healthy controls.
Natural language processing
The SD dataset is composed almost entirely of struc-
tured questionnaire items, but free response and text
transcription items are also included. One question on
the survey asked the interviewer to transcribe text found
on any drug containers in the household, and the second
free response item asked the interviewer to write down
any other pertinent information about the interview that
he/she felt was useful.
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We implemented techniques based on text mining and
natural language processing to capture the “free response”
information [25-29]. We were interested in identifying
text signals that held some diagnostic value and then in
“tokenizing” the free text into data features that could be
used by computational algorithms. For example, for the
text feature “alcohol”, an interview would have a 1 if that
word appeared in the free response section and a 0 if it
did not. In addition, some words or expressions are es-
sentially synonymous for data classification purposes (for
example, “alcohol”, “alcoholism”, and “alcoholic”). In a
process called stemming, we treat the root of the word (in
this case, “alcohol”) as the actual text feature instead of
the entire word itself. To take care of misspellings, mis-
translations, or variations in medical terminology we
utilized the dictionary developed for VA analysis that
mapped roughly synonymous words to a single text fea-
ture. We utilized in this process the TM package in R [30].
Train-test environment
A critical component of developing and validating data
classification models is constructing an appropriate val-
idation environment. A given model must be “trained”
on a randomly selected portion of the dataset and then
“tested” on an uncontaminated separate portion of the
dataset. In this study we split the entire dataset into 75%
train data and 25% test data, where the components are
sampled by the outcome variable (in this case, the dis-
ease). Thus, if there were 100 cirrhosis cases in the full
dataset, then 25 would be sampled into the test data and
75 into the train data. This train-test split is repeated
500 times to conduct 500 simulations and to estimate
uncertainty around the predictive validity estimates.
Previous research in VA has shown that i) predictive
validity is artificially enhanced when test and train com-
position are similar and ii) the estimated performance of
a method is largely a function of the cause composition
of the test dataset [31]. To solve the second problem,
following Murray et al. [31], we varied the composition
of the test data by resampling with replacement based
on an uninformative Dirichlet distribution.
Models
Four data-driven models for VA classification were tested
and validated as part of the PHMRC study. We were able
to adapt each of these models for use in the SD analysis.
Three of the models – Tariff [18], Simplified Symptom
Pattern [32], and Random Forest [16] – are capable
of diagnosing individual subjects and estimating cause-
specific mortality fractions (CSMFs), or in our case, cause-
specific prevalence fractions (CSPF), while the King-Lu
[33] algorithm can only estimate CSMFs (or in our case
CSPFs). The selected method for this analysis was Tariff,
which has shown a good performance in previous studies
[23] and is described in detail.
Tariff is a simple additive algorithm that uses the cal-
culation of a “tariff” (similar to a Z-score) for each
cause-feature combination in the training data followed
by a summation and ranking function to predict the
most likely causes for each subject in the test dataset.
The Tariff for a given cause-feature combination quan-
tifies how uniquely and strongly predictive a given data
feature is for a given cause. The Tariff for cause i and
feature j is calculated as:
Tarif f ij ¼
xij − Median xj
 
Interquartile Range xj
where Tariffij is the tariff for cause i, feature j, xij is the
fraction of subjects with cause i for which there is a posi-
tive response for item j, median (xj) is the median fraction
with a positive response for feature j across all causes, and
interquartile range xj is the interquartile range of positive
response rates for feature j averaged across causes.
For each subject in the SD dataset, we compute summed





The Tariff scores for each cause are ranked across all
subjects, and the top-ranked cause for each subject is
assigned as the diagnosis for that subject.
Analysis
We assessed and compared the capability of the SD
model using the VA performance metrics described by
Murray et al. [31]. SD is capable of i) predicting whether
or not an individual suffers from different NCDs and ii)
estimating the fraction of individuals in a population
who suffer from a given condition. Consequently, the
performance of SD should be quantified in both the in-
dividual and population domains.
Chance-corrected concordance
Chance-corrected concordance (CCC) is a measure of a
method’s ability to correctly diagnose a condition in an
individual. However, because random assignment of N
different causes would be correct 1/N times, this metric
must also be adjusted for random chance [31].









where TP is true positives, FN is false negatives, and N
is the number of causes or conditions (11 in this study).
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Cause-specific prevalence fraction (CSPF) accuracy
Following Murray et al. [31], we used CSPF accuracy as a
metric to assess the ability of the questionnaire to estimate
prevalence fractions, analog to CSMF in a verbal autopsy
study. In our case, CSPF accuracy, which is an aggregate











Where the superscript for CSPF refers to true (“t”) or
predicted (“pred”) cause fractions. The denominator re-
flects the maximum possible CSPF error in the given
test split:
CSPF Maximum Error ¼ 2 1‐Minimum CSPFjt
  
Hence, CSPF accuracy can be described as 1 minus the
sum of absolute errors divided by the maximum error. A
CSPF accuracy of 1 would indicate perfect cause fraction
predictions, while 0 would indicate the worst possible
model.
We assessed the performance of SD in the two metrics
described above and in terms of cause fraction absolute
error, which allows for inspection of its performance in
measuring prevalence fractions for each cause. Each type
of validation was conducted across 500 splits of data.
We tested each method under two conditions: with all
data features and with all data features excluding HCE
information.
We also analyzed whether SD methods systematically
over- or underestimate the prevalence fractions. Using
the true and estimated prevalence fractions from 500
splits, we conducted linear regressions where the esti-
mated prevalence fraction was a function of the true
prevalence. Stata, R, and Python were used for all ana-
lysis and data management.
Results
Symptomatic diagnosis interviews
We collected 1,379 questionnaires with an accompany-
ing gold standard diagnosis. The number of SD inter-
views conducted for each of the 10 conditions and for
controls are provided in Table 1. This table also provides
the age and sex distribution by condition and shows that
the project gathered approximately the target number of
interviews or more for each condition and for the con-
trol group.
Although questionnaires were analyzed using all of the
different methods mentioned above, this section pre-
sents only the results derived from the Tariff method.
Results from analysis using other methods are presented
in Additional file 4 as robustness checks.
Table 2 provides the mean CCC for the Tariff method
across 500 splits, with and without HCE. Overall, CCC
increases with HCE. We calculated the estimated and
true prevalence cause fractions for each test split of data.
These true and estimated cause fractions were used to
calculate absolute errors and CSPF accuracy across 500
splits. Table 2 also provides the median CSPF accuracy
for the Tariff method across 500 splits, with and without
HCE information. As in the case of CCC, accuracy in-
creased with the inclusion of HCE information.
Figures 1 and 2 show CCC and prevalence fraction ab-
solute errors for each specific condition with and with-
out HCE. We observed that depression has high CCC
regardless of whether HCE information is used, while vi-
sion loss, cataracts, and osteoarthritis experience lower
performance. Some causes, such as asthma, rheumatoid
arthritis, cirrhosis, or angina, increase their CCC more
than others by the inclusion of HCE information. Preva-
lence fraction absolute errors are higher in the analysis
without HCE, and are smaller for causes like rheumatoid
arthritis, asthma, and cirrhosis.
In the analysis to check whether SD systematically
over- or underestimates the prevalence fractions, we con-
ducted linear regressions where the estimated prevalence
Table 1 Characteristics of the study participants for each condition
Condition Number of interviews Mean age Standard deviation age % Male
Angina pectoris 107 62.7 11.9 69%
Asthma 117 42.7 12.8 26%
Chronic obstructive pulmonary disease 108 69.1 11.0 43%
Cataracts 108 68.1 13.4 38%
Cirrhosis 104 51.4 11.3 81%
Depression 100 39.4 15.2 30%
Hearing loss 205 47.3 9.1 29%
Osteoarthritis 107 62.1 11.5 20%
Rheumatoid arthritis 119 52.1 12.3 8%
Vision loss 106 54.9 16.8 39%
Control 198 40.3 6.0 14%
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fraction was a function of the true one. An illustration of
this analysis for angina pectoris with HCE is provided in
Figure 3a. This figure and associated coefficient and inter-
cept illustrate how the SD for this cause tends to slightly
underestimate the prevalence of angina pectoris, except
for very low true prevalence fractions. In contrast, the
equivalent scatterplot in Figure 3b for hearing loss shows
more overestimation when the true prevalence fraction is
0 but a general systematic underestimation for larger pre-
valence fractions.
Cross-classification and cause aggregation
We found that the SD achieved high CCC for the causes of
angina pectoris, depression, and cirrhosis. However, vision
loss and osteoarthritis experienced lower performance. To
explore if there was some cross-classification between
vision loss with cataracts due to the similar clinical presen-
tation of these conditions, we used cross-classification or
“confusion” matrices. An example of a confusion matrix
for a single split (prior to undergoing the Dirichlet-based
resampling) is shown in Additional file 5. This confusion
Table 2 Mean chance-corrected concordance and median cause-specific prevalence fraction accuracy across causes
including uncertainty intervals, with and without health care experience (HCE), using the Tariff method
Chance-corrected concordance (CCC) Cause-specific mortality fractions accuracy
CCC estimate 95% uncertainty interval CCC estimate 95% uncertainty interval
No HCE 53.4% (53.2–53.9%) 0.772 (0.765–0.779)
With HCE 66.1% (65.6–66.5%) 0.826 (0.818–0.834)
Figure 1 Cause-specific chance-corrected concordance with and without health care experience.
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matrix shows how 8 out of 24 true vision loss cases were
correctly classified as vision loss, but 8 were misclassified
as cataracts. Out of 27 true cataracts cases, 10 were cor-
rectly classified as cataracts, but 5 were misclassified as
vision loss.
This investigation of cause assignments indicated that
there could be considerable cross-classification but also
that the features most strongly associated with vision
loss or cataracts had a much weaker association than
other feature-cause combinations. This suggests the pos-
sibility of increasing performance by combining similar
causes. So, instead of differentiating between vision loss
and cataracts, we generated a combined category of “vi-
sion loss or cataracts.” We measured the effect of this
aggregation on performance and found that overall CCC
increased by approximately 3% in absolute terms and
that CSPF accuracy increased by 0.032 in absolute terms
(Table 3). The prevalence fraction absolute error and
CSPF accuracy for the nine-cause aggregation is shown
in Additional file 6.
Discussion
The PHMRC SD study presents a novel source of data
and an innovative application of VA research to compu-
tational estimation of NCD burden. The study identified
cases of 10 NCDs that had been diagnosed with gold
standard criteria and then conducted a questionnaire with
over 100 patients for each condition. The questionnaire
was designed to estimate prevalence using data-driven
methods, specifically the Tariff method, which has been
validated in VA studies. By applying Tariff to the PHMRC
dataset, we sought to demonstrate that the questionnaire-
based approach of SD may be a valuable asset to future
epidemiological research concerning the burden of NCDs.
We further simulated the application of Tariff in the field
by testing the performance with the inclusion/exclusion of
HCE information, which allowed us to determine the via-
bility of using Tariff in areas with no health care, and by
testing performance in samples of test data with random
cause compositions. The results of the study can thus be
considered robust due to i) the gold-standard validation of
the questionnaire responses, ii) the calculation of predict-
ive validity in various test data compositions, and iii) com-
parisons with the performance of current epidemiological
measurement approaches.
We observed that the Tariff method applied to the SD
questionnaire is a promising approach for collecting
prevalence data on the NCDs outlined in this study.
Tariff was capable of estimating prevalence fractions
within 3% for each condition. Additionally, 5 of the 11
conditions have a CCC of over 60%. Estimation of preva-
lence fractions within 3% for these chronic conditions
would allow for higher resolution epidemiological infor-
mation in areas with sparse data, and for the conditions
with high performance in terms of CCC, this techno-
logy could be used for diagnoses in the field without
requiring extensive medical expertise or other tools or
resources.
Figure 2 Cause-specific prevalence fraction absolute errors with and without health care experience.
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Figure 3 True and estimated prevalence fractions using the Tariff Method with health care experience for 500 splits for (a) angina
pectoris and (b) hearing loss.
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While Tariff demonstrated accurate results in measur-
ing certain conditions, it was found to be less accurate
in others. The lower performance of Tariff in identifying
vision loss, cataracts, and osteoarthritis can be explained
partially through cross-classification error, but the rela-
tively poor performance of hearing loss with Tariff may
be a surprising result since it seems reasonable that hear-
ing loss patients would express somewhat salient signs
and symptoms compared with other conditions. The ana-
lysis of endorsement rates of all features by true cause
showed that one of the obstacles in diagnosing hearing
loss based on this questionnaire derives from a lack of
items with a high endorsement rate for hearing loss but
not for other causes. For example, one item asks, “Have
you ever had your hearing checked by a provider?” While
the endorsement rates for hearing loss are high (91.2%)
for this item, cases with the other conditions also endorse
this item at a fairly high frequency (82.2% of the controls
and 71.8% of the asthma cases). In contrast, causes that
had better performance tend to have an item that has a
high endorsement rate for that cause but not for others.
For example, the question “Have you had a period lasting
several days when you lost interest in most things that you
usually enjoy such as pastimes, relationships, or work?”
has a 90% endorsement rate among depression cases, but
no higher than 30.3% endorsement for other causes.
In our literature-based comparison to current methods,
we observed that Tariff was capable of matching or out-
performing the questionnaire-based methods such as the
Rose questionnaire and the composite international diag-
nostic interview (CIDI) depression questions in terms of
prevalence estimation (Table 4). The SD questionnaire es-
sentially includes the Rose questionnaire, CIDI depression
questions, and the World Health Survey asthma ques-
tions. Since, in theory, the positive endorsement of the
items for these questions should essentially ensure correct
diagnosis, it may be surprising that the data-driven SD
methods can achieve higher performance than these cur-
rent approaches. That is, we did not need to “tell” Tariff
that endorsement of the Rose questions indicates angina
pectoris; rather, Tariff determined those relationships on
its own. The result in some ways parallels the finding in
VA research that computational methods can compete
with and possibly outperform physician-certified autopsy.
Current estimation of COPD, rheumatoid arthritis,
osteoarthritis, vision loss, hearing loss, cirrhosis, and cata-
racts can be undertaken with a high level of accuracy in
a clinical setting, but their diagnosis requires specialized
diagnostic equipment and extensive medical training. Cer-
tainly, it is desirable to collect the most accurate informa-
tion possible, but access to these tools and resources is
not possible in all areas of the world. Furthermore, SD has
the unique advantage of being able to collect information
on every condition after conducting a single interview.
The alternative approaches of carrying diagnostic equip-
ment for each of these conditions or conducting multiple
cause-specific diagnostic surveys in parallel seems very
implausible. As discussed in the introduction, this is an
unfortunate paradox since the areas lacking these re-
sources are also likely the areas that have the worst health.
SD, in this regard, is a valuable alternative to collecting
more refined information in a resource-poor setting. A
household survey can be conducted virtually anywhere in
the world. Currently, Demographic and Health Surveys
and World Health Surveys cover areas of the world
such as Sudan, Cote d’Ivoire, and Democratic Republic of
Congo, for example. If access to the tools and expertise to
Table 3 Chance-corrected concordance and cause-specific
prevalence fraction accuracy for nine-cause aggregation










Angina pectoris 80.1 84.1
Asthma 68.9 76.4
Arthritis 63.4 70.3
Vision loss or cataracts 57.0 57.4
Chronic obstructive pulmonary disease 41.6 49.5
Hearing loss 47.1 47.9
Control 56.5 57.8
Mean chance-corrected concordance (%) 65.0 69.2
Median cause-specific prevalence fractions accuracy 0.842 0.858
Table 4 Absolute errors in prevalence estimates from SD method to literature-based approaches
Condition Test Absolute error (95% CI) Symptomatic diagnosis-Tariff
method with health care experience
absolute error (95% CI)
Asthma World Health Survey (WHS): Doctor (MD) diagnosis (Dx) [34] 0.023 (0.020, 0.025) 0.014 (0.012, 0.016)
WHS MD Dx OR asthma medications (Rx) [34] 0.023 (0.020, 0.025)
WHS MD Dx OR asthma Rx OR wheezing/whistling attacks [34] 0.092 (0.087, 0.095)
Angina pectoris Rose questionnaire [35,36] 0.082 (0.073, 0.088) 0.020 (0.018, 0.022)
Depression Composite international diagnostic interview questionnaire [37] 0.059 (0.054, 0.064) 0.016 (0.015, 0.017)
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diagnose these conditions in these areas is unavailable,
then SD-based epidemiology could be a practical alterna-
tive. The use of SD methods in low-resource or inaccess-
ible areas to identify and focus attention on the chronic
disease burden could also help address the aforemen-
tioned paradox. Furthermore, training field workers to
conduct an SD survey seems likely to be less expensive
than making available the resources to diagnose all of the
conditions outlined in this study. Cumulatively, this flexi-
bility makes SD a compelling alternative strategy for
measuring the burden of these conditions.
Limitations
Our study had some inherent limitations. One of the main
limitations and questions in VA research is that question-
naire responses for deaths that occur in the community
could be systematically different than the responses from
deaths that occur in hospitals. If the response patterns are
sufficiently different, then the computational methods
could perform differently than expected when they are im-
plemented in the field. However, this limitation, which ap-
plies also to SD, is essentially a normative question. It is
not possible to develop data-driven models unless this
limitation is accepted, and as previous research in VA
has shown, data-driven models can match or outperform
expert-based models [23]. To deal with this limitation, we
drew 500 samples with different prevalence of NCDs
under study from our study sample, and attempted to
simulate cases where the respondent did not have access
to health care by conducting analyses in which we with-
held HCE features.
A second limitation is that the study did not include
individuals whose address could not be found, and this
may potentially introduce a bias if individuals who were
not found are systematically different in their socioeco-
nomic status or other characteristics from the ones who
were located. The main reason for not locating cases
was that the patient provided the address of a relative to
have access to some hospitals in Mexico City; therefore,
we do not think that it is likely that there are clear dif-
ferences in the socioeconomic status of these individuals.
However, it is possible that the study may exclude some
individuals from lower socioeconomic status that could
not be located.
Since prevalence data are sparse in many areas of the
world, it is important to consider the potential imple-
mentation of the SD methods outlined in this study in
countries besides Mexico. The 10 NCDs considered in
this study are also highly prevalent in areas of Africa and
Asia, and this consideration raises the question if there
exist systematic cultural variations in questionnaire re-
sponse data. It seems plausible that response patterns
for something as sensitive as a medical interview will have
cultural idiosyncrasies. This limitation can be addressed
by further collection of validated SD questionnaire re-
sponses in other countries. In fact, additional validated SD
questionnaire response data would strengthen the per-
formance of the existing models. Furthermore, the com-
putational SD methods can readily be retrained on any
further validation data collected, though similar to VA,
the general SD approach will be strongest if a central data
repository is maintained such that the central Tariff matrix
can be continually updated.
Finally, while the inclusion of healthy controls is ge-
nerally a strength in this study, it is possible that the
healthy controls can be ill with minor conditions. The
inclusion of these controls is important, however, be-
cause it allows for a model to predict that a person does
not suffer from a given condition despite possibly pre-
senting some of the signs and symptoms associated with
that condition. For example, 50% of the controls report
a non-productive cough, which is not a dramatically
lower endorsement rate than asthma, in which 58% of
cases reported a non-productive cough. The inclusion of
controls highlights one of the important differences be-
tween SD and VA: every person who dies has an under-
lying cause of death, but not every living person has an
underlying illness. There were also some differences in
the characteristics of the health controls compared to
the rest of the study participants as shown on Table 1;
specifically, the controls tend to be slightly younger and
are more frequently female than the other participants.
Future implementation
The central question for future implementation of SD
methods is whether this method provides adequate ac-
curacy and usability to be used for epidemiologic data
collection. Certainly, in the hierarchy of epidemiological
data, self-reported signs and symptoms in an interview
setting has historically been considered relatively lower-
quality data; however, one of the important findings in
this study was that the methods and criteria used in
traditional epidemiologic studies of these diseases was in
fact less accurate than the methods tested here. Thus,
this study provides promising evidence that self-reported
signs and symptoms combined with techniques such as
the Tariff method may be more valuable than previously
understood. Regardless, it will be important to further
validate the performance of SD methods, particularly by
using further cross-validation with data collected from
outside this study. Similarly, while this study focused on
selected NCDs in one country, it will be important to
conduct further research both in other countries and
with other conditions in order to generalize the capabil-
ities of SD. This will be particularly important when it
comes to NCDs with more protean clinical presenta-
tions, in areas where it is more difficult to collect data,
and in patients who may have multiple comorbidities.
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Ideally, future work will further develop the capabilities
of SD in assessing the prevalence of other NCDs in
other areas of the world, contributing to a better under-
standing of the burden of NCDs globally.
With these considerations, the implementation of the
tool developed in this study requires two further steps
for interested users. The first step is facilitating the im-
plementation of the questionnaire itself. The question-
naire is provided in this study and can hypothetically be
used as-is. However, current work in VA is moving to-
ward using tablet devices that can use questionnaire
software such as Open Data Kit Collect to facilitate data
collection. Options such as geotagging, digital imagery,
and improved instrument clarity/organization make this
an even more compelling data collection approach. The
second required step is developing a user-friendly soft-
ware package that readily conducts the method des-
cribed in this study. Reducing these barriers will facilitate
more rapid use of the methods outlined in this study to
improve the collection of health information for NCDs.
Conclusions
The SD study had the goal to develop better instruments
and methods for measuring population health, particu-
larly in resource-poor settings where clinicians are not
available to assist in diagnosis of NCDs. To this end, the
study was a success in that it found that the Tariff me-
thod could accurately measure the prevalence of several
important conditions. This study provides a promising
way to improve strategies for population health measure-
ment and to produce instruments that are scientific, stan-
dardized, and widely applicable across different resource-
poor settings. Although more work is required to test
this method in other NCDs and in different settings,
the SD questionnaire combined with the Tariff method,
has the potential to help researchers better measure the
burden of NCDs and to additionally enable policymakers
and researchers to help address persistent inequities in
health outcomes in both the developed and the deve-
loping world.
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